🔗 Visit the ClinicalTrials.gov page for NCT02409355
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Checkpoint inhibitors in lung cancer: latest developments and clinical potential. | Ther Adv Med Oncol | 2016 | 0.96 |
| 2 | Advances in immunotherapy for treatment of lung cancer. | Cancer Biol Med | 2015 | 0.95 |
| 3 | The effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune response. | Oncotarget | 2016 | 0.79 |
| 4 | Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. | Eur J Cardiothorac Surg | 2015 | 0.77 |
| 5 | Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targets. | Nat Rev Clin Oncol | 2015 | 0.76 |
| 6 | Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer? | Transl Lung Cancer Res | 2016 | 0.75 |
| 7 | Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatment. | Onco Targets Ther | 2016 | 0.75 |